Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Oral Health, Saliva Bacteria, and Disease Activity in Children With JIA: A Cross-Sectional Study. (JIA)

28 agosto 2026 aggiornato da: Biyu Shen, Shanghai Jiao Tong University School of Medicine

Association of Oral Health Status and Salivary Microbiota With Disease Activity in Children With Juvenile Idiopathic Arthritis: A Cross-Sectional Study.

The goal of this observational study is to learn about the relationship between disease activity and oral health status in children with juvenile idiopathic arthritis (JIA). The main question it aims to answer is:

Is disease activity associated with oral health in children with JIA? Do children with active disease have poorer oral health compared to those in clinical remission? Participants already receiving routine rheumatology care for JIA will undergo a single study visit. At that visit, disease activity will be assessed, an oral health examination will be performed, and saliva samples will be collected. Based on the disease activity assessment, participants will be classified into two groups: those with active disease and those in remission. Oral health measures and saliva-related parameters will be compared between the two groups.

This study is expected to provide preliminary evidence to help identify JIA children at higher risk of oral health problems and to support the integration of oral health evaluation into comprehensive JIA management.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Descrizione dettagliata

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, characterised by alternating periods of active disease and remission. Despite therapeutic advances, joint involvement in the hands, wrists, or temporomandibular joints can hinder daily oral hygiene practices, and long-term medication use may affect the oral microenvironment, increasing the risk of dental caries and gingivitis. In current routine rheumatology follow-up in China, oral health status is not systematically assessed; it is usually addressed only when the child complains of symptoms, leading to delayed recognition and intervention.

This single-centre, cross-sectional observational study aims to compare oral health status between JIA children with different levels of disease activity and to preliminarily explore the association of salivary local biological characteristics with disease activity. No intervention is applied. All data are collected at a single time point during a regular outpatient visit.

Study Population Children aged 6 to 16 years who meet the ILAR classification criteria for JIA are eligible. Exclusion criteria include use of systemic antibiotics within the past 3 months, ongoing fixed orthodontic treatment, presence of other systemic conditions known to affect oral health (e.g., diabetes, Sjögren's syndrome), or inability to cooperate with the examination.

Grouping and Assessments At enrolment, two experienced rheumatologists independently classify each participant as having "active disease" or "clinical remission" based on standardised clinical assessment (joint examination, physician global assessment, and routine laboratory inflammatory markers). During the same visit, the following are completed: (1) collection of demographic and disease-related data; (2) a comprehensive oral clinical examination conducted by trained dentists, covering dental hard tissues, periodontal soft tissues, and oral hygiene status; and (3) collection of unstimulated whole saliva for subsequent analysis of local inflammatory markers and microbial community profiles. All data are recorded using coded identifiers to protect participant privacy.

Statistical Analysis Oral health parameters will be compared between the two groups, with multivariable methods used to control for potential confounders such as age, sex, and disease duration. The correlation between continuous disease activity scores and composite oral health indices will be evaluated. Saliva data will be explored for associations with disease activity and oral health parameters.

Clinical Significance This study addresses a long-neglected but clinically relevant question: whether disease activity in JIA is associated with oral health status. If children with active disease show poorer oral conditions, this would support the need for rheumatologists to actively inquire about oral hygiene habits and dental history during follow-up, and to consider incorporating basic oral health screening (e.g., questions on brushing, gum bleeding, toothache) into routine visits. Through this work, we aim to promote clinical awareness of oral health issues in children with chronic diseases and advocate for the inclusion of oral health assessment as a fundamental component of JIA chronic disease management, fostering collaboration between paediatric rheumatology and dentistry, and ultimately improving patients' quality of life.

Tipo di studio

Osservativo

Iscrizione (Stimato)

200

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Biyu Shen, PhD
  • Numero di telefono: 86+13862937317
  • Email: shenbiyu@126.com

Backup dei contatti dello studio

  • Nome: Yuan Yuan Xiang, Graduate Student
  • Numero di telefono: 86+15995792738
  • Email: 2115746605@qq.com

Luoghi di studio

    • Pudongxinqu
      • Shanghai, Pudongxinqu, Cina, 200135
        • Reclutamento
        • Shanghai Children's Medical Center, Lujiazui Campus, affiliated to Shanghai Jiao Tong University School of Medicine
        • Contatto:
          • Biyu Biyu Shen, PhD
          • Numero di telefono: 86+13862937317
          • Email: shenbiyu@126.com

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Bambino

Accetta volontari sani

Sì

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Children aged 6 to 16 years diagnosed with juvenile idiopathic arthritis according to the ILAR classification criteria (excluding systemic-onset subtype), recruited from both inpatient and outpatient rheumatology services at the study site. Healthy controls aged 6 to 16 years with no history of chronic inflammatory or autoimmune diseases are recruited from the same city. All participants must be able to cooperate with oral examination and saliva collection. Written informed consent is obtained from parents or legal guardians, and assent from children.

Descrizione

Inclusion Criteria:

  • Children aged 6 to 16 years.
  • Diagnosed with juvenile idiopathic arthritis according to the International League of Associations for Rheumatology (ILAR) classification criteria, excluding the systemic-onset subtype.
  • For the active disease subgroup, all of the following must be met:

    1. Presence of active arthritis as determined by the attending rheumatologist;
    2. Planned initiation or adjustment of disease-modifying antirheumatic drugs (DMARDs) or biologic agents within 1 month after enrolment;
    3. Meeting the following disease activity criterion: JADAS-27 score > 1. For the remission subgroup, the following must be met: JADAS-27 score ≤ 1 and clinically stable disease.
  • Able to cooperate with oral examination and saliva sample collection.
  • Written informed consent provided by a legal guardian, with assent obtained from the child.

Exclusion Criteria:

  • Use of systemic antibiotics within 3 months prior to enrolment, or use of mouthwash containing antibiotics, corticosteroids, or chlorhexidine within 1 month prior to enrolment.
  • Diagnosis of other autoimmune diseases (e.g., systemic lupus erythematosus, Sjögren's syndrome), chronic inflammatory diseases (e.g., inflammatory bowel disease), diabetes mellitus, congenital heart disease, or other systemic conditions that may affect the study outcomes.
  • Presence of acute infection at the time of sampling or examination (e.g., body temperature > 37.5°C, upper respiratory tract infection, acute oral infection).
  • Significant cognitive or behavioural impairment that prevents cooperation with study procedures.
  • Ongoing or planned orthodontic treatment within the next 6 months.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
JIA group
Children aged 6 to 16 years diagnosed with juvenile idiopathic arthritis according to the ILAR classification criteria, receiving routine rheumatology care at the study site. Participants are classified into active disease or clinical remission subgroups based on standardised clinical assessment at enrolment. No intervention is applied.
Healthy Control Group
Healthy children aged 6 to 16 years with no history of chronic inflammatory or autoimmune diseases, recruited from the same city or community as the JIA group. No intervention is applied.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Oral Health Status
Lasso di tempo: At baseline, during a single routine outpatient visit immediately after written informed consent is obtained.
A comprehensive oral health examination is conducted by trained dentists in accordance with the World Health Organization Oral Health Surveys: Basic Methods. The examination covers dental hard tissue status, periodontal soft tissue status, oral hygiene status, oral mucosal assessment, and oral health-related behaviours. For dental caries assessment, each tooth is visually and tactilely examined under standardised lighting, and indices are calculated for permanent and primary dentition as appropriate. Periodontal status is evaluated using standardised probes to assess gingival bleeding and pocket depth. Oral hygiene is assessed following WHO recommendations; prior to evaluation, a disclosing agent is applied to tooth surfaces to visualise plaque, enabling standardised scoring of debris and calculus on representative surfaces. The oral mucosa is inspected for any soft tissue abnormalities. Oral health behaviours, including toothbrushing habits, dietary practices, and dental attendance.
At baseline, during a single routine outpatient visit immediately after written informed consent is obtained.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Salivary Microbiota
Lasso di tempo: Baseline visit (fasting morning)
The samples are analysed for microbial composition using 16S rRNA gene sequencing, assessing microbial diversity, relative abundance of major taxa, and compositional differences between study groups. In addition, levels of soluble inflammatory proteins are measured to evaluate local inflammatory status.
Baseline visit (fasting morning)
Disease Activity Assessment
Lasso di tempo: Baseline visit
Disease activity is assessed by experienced rheumatologists using standardised clinical evaluation at the baseline visit. The assessment includes joint examination (swollen and tender joint count), physician global assessment of disease activity on a visual analogue scale, and routine laboratory inflammatory markers (erythrocyte sedimentation rate and C-reactive protein level). Based on the combined findings, participants are classified as having active disease or being in clinical remission.
Baseline visit

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

  • [1]Klingberg G.,Hallberg U.Oral health-Not a priority issue A Grounded Theory analysis of barriers for young patients with disabilities to receive oral health care on the same premise as others.Eur.J.Oral Sci.2012;120:232-238. [2]Szabo Y Z,Slavish D C,Graham-Engeland J E.The effect of acute stress on salivary markers of inflamma-tion:a systematic review and meta-analysis[J].Brain Behav Immun,2020,88:887-900. [3]Walton AG,Welbury RR,Thomason JM,Foster HE.Oral health and juvenile idiopathic arthritis:a review.Rheumatology(Oxford).2000 May;39(5):550-5. [4]LANGE L,THIELE G M,MCCRACKEN C,et al.Symptoms of periodontitis and antibody responses to Porphyromonas gingivalis in juvenile idiopathic arthritis.Pediatr Rheumatol Online J,2016,14(1):8. [5]Romero-Sanchez C,Malagon C,Vargas C,et al.Porphyromonas gingivalis and IgG1 and IgG2 subclass antibodies in patients with juvenile idiopathic arthritis[J].J Dent Child(Chic),2017,84(2):72-79. [6]Titusson C,Jansson L,Modin C,Lundmark A,Eriksson K,Adler L,Yucel-Lindberg T.Salivary Inflammatory Mediator Profiles in Periodontal and Peri-Implant Health and Disease:A Cross-Sectional Study.Clin Implant Dent Relat Res.2025 Feb;27(1):e70002. [7]Halbig JM,Jönsson B,Gil EG,Åstrøm AN,Rypdal V,Frid P,Augdal TA,Fischer J,Cetrelli L,Rygg M,Lundestad A,Tylleskär K,Nordal E;Norwegian JIA Study-Temporo-mandibular Involvement,Oral Health,Uveitis,Bone Health,Quality of Life in Children with Juvenile Idiopathic Arthritis.Oral health-related quality of life,impaired physical health and orofacial pain in children and adolescents with juvenile idiopathic arthritis-a prospective multicenter cohort study.BMC Oral Health.2023 Nov 20;23(1):895. [8]Savioli C,Silva CA,Ching LH,Campos LM,Prado EF,Siqueira JT.Dental and facial characteristics of patients with juvenile idiopathic arthritis.Rev Hosp Clin Fac Med Sao Paulo.2004 Jun;59(3):93-8.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

1 luglio 2026

Completamento primario (Stimato)

1 luglio 2027

Completamento dello studio (Stimato)

1 luglio 2027

Date di iscrizione allo studio

Primo inviato

28 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

28 agosto 2026

Primo Inserito (Effettivo)

2 settembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

2 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

28 agosto 2026

Ultimo verificato

1 agosto 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • SCMCIRB-K2026053-1

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

This study does not involve a clinical trial or interventional design. The data collected include sensitive oral health and biological information from children, and participant consent obtained does not cover data sharing with external researchers. Should circumstances change in the future, we will update this plan accordingly.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .